Memantine hydrochloride 99% CAS NO.41100-52-1

Hydrochloric acid dollars just was developed by the German Merz company alzheimer's treatments, is a kind of new type, low to moderate affinity, voltage dependence, non-competitive N - methyl - D - aspartate (NMDA) receptor antagonist medicine, non-competitive block NMDA receptor, reduce NMDA glutamate receptor euphoria, prevent apoptosis, improve memory, is a new generation of drugs to improve cognitive function.

 

In February 2002, the European patent medicines commission (CPMP) approved its use for the treatment of moderate and severe alzheimer's disease, and it was put on the market in Germany in August of the same year. On October 17, 2003, it was approved by the us food and drug administration (FDA) for the treatment of moderate and severe alzheimer's disease. Further studies have shown that memantine hydrochloride is also effective in patients with mild and moderate alzheimer's disease.

 

1. Combined use with huperzine a: huperzine a is a drug extracted from huperzine, a traditional Chinese medicine, and it is a reversible competitive cholinesterase inhibitor. Meminguon has different binding abilities to different glutamate receptor subtypes or ion channels, reducing the excitotoxic effects of glutamate, thus treating AD. AD patients not only have a variety of neurotransmitter changes, but also have abnormal postsynaptic receptors. Therefore, the combination of cholinesterase inhibitors and glutamate receptor inhibitors can play a synergistic role.

 

2. Combination with donepezil: as the second-generation cholinesterase inhibitor, donepezil has high selectivity of cholinesterase in the central nervous system, long half-life and lower toxicity than huperzine a. Donepezil and huperzine a act on different nerve conduction systems, and when they are used together, a synergistic effect can be produced to enhance the efficacy. Although the specific mechanism of action has not been discovered, it has been proved that patients with moderate or severe AD who are treated with memantine hydrochloride in combination with other drugs will have better therapeutic effects.

 

3. Combined use with nimodipine: nimodipine, a Ca2+ antagonist of dihydropyridine, can act on nerve cells, cerebrovascular cells and glial cells of the central nervous system, and can significantly expand the diameter of cerebral vessels and meninges, thus delaying the cognitive decline of patients to a certain extent. When nimodipine is combined with memantine hydrochloride, its different pharmacological action links and mechanisms may complement each other to produce better therapeutic effect.

 

4. With the combined use of ginkgo biloba on: the main ingredients of flavonoids from ginkgo biloba leaves and tomato in lipid compounds, antithrombotic, anticoagulation, antiplatelet aggregation, antioxidant and lipid effect, improve the permeability of blood vessel walls and reduce the brain injury, for the brain microvascular smooth muscle cells have a protective effect, the protection of "vascular damage" has obvious effect [14]. Vascular factors play an increasingly important role in the pathogenesis of AD. A large number of epidemiological, clinical and basic studies have shown that many risk factors related to vascular factors or hemodynamics can increase the risk of AD. Therefore, memangang hydrochloride, which ACTS on NMDA receptors, can play a synergistic role in combination with ginkgo biloba.

 

The descriptions, properties, and synthesis methods of memantine hydrochloride are compiled by the Chemicalbook. Currently, cholinesterase inhibitors (donepezil, carbaratine, galantamine) and megamind hydrochloride are approved for the treatment of alzheimer's disease.